Samsung Biologics shares buoyed by Biogen's successful Alzheimer treatment test

Kang Min-woo and Minu Kim 2022. 9. 30. 11:57
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Source: Samsung Biologics Co.]
Samsung Biologics shares remained positive Friday morning after rallying on the previous day thanks to improved sentiment across the biotech sector from news that Alzheimer’s disease drug being developed by Biogen and Eisai demonstrated efficacy in a phase 3 clinical trial.

Shares of Samsung Biologics started Friday’s trading session a bit higher after a 6 percent jump in the previous day, taking back the 800,000 won ($559) range in six days. It inched up 0.62 percent at 818,000 won.

On Thursday (local time), Biogen and Eisai announced that the anti-amyloid antibody lecanemab met its primary endpoint by reducing clinical decline relative to a placebo by 27 percent. Biogen shares jumped nearly 40 percent on the announcement.

Biogen plans to submit for full approval of lecanemab to the U.S. FDA by the first quarter of next year.

Analysts say the clinical progress of Biogen will benefit global contract manufacturers like Samsung Biogen. NH Investment & Securities estimates that more than 95 percent of Samsung Biologics’ drug substance sales come from contract manufacturing of monoclonal antibody therapies like lecanemab.

The overall monoclonal antibody therapy market is projected to grow by 9 to 10 percent annually and this has a significant impact on the permanent growth rate of contract manufacturers as a stock price is valuated on the expected future cash flows discounted in today’s value on a per-share basis, said NH analyst Park Byung-kuk.

Samsung Biologics has a long-standing partnership with Biogen. They established Samsung Bioepis in a joint venture, which was fully acquired by Samsung Biologics in January.

[ⓒ Maeil Business Newspaper &, All rights reserved]

Copyright © 매일경제 & 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?